Epidemiology, antifungal susceptibilities, and risk factors for invasive candidiasis from 2011 to 2013 in a teaching hospital in southwest China

Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
Shuli PuLiping Zhang

Abstract

Invasive candidiasis (IC) is the most common cause of invasive fungal infections. Identification of risk factors for such infection may help in the empirical therapeutic decision-making process. We conducted this study to characterize the clinical epidemiology of such infection and to differentiate risk factors between Candida albicans and Candida non-albicans species. We retrospectively evaluated patients with IC from 2011 to 2013. Clinical data, antibiotic therapy, underlying condition, and invasive procedures were analyzed and compared between C. albicans and C. non-albicans species. C. albicans was the most frequently isolated Candida species (48.6% of all IC patients), although C. non-albicans spp. were more commonly isolated overall. C. albicans, Candida tropicalis, and Candida parapsilosis have a high susceptibility rate to all antifungal agents (>90%), whereas Candida glabrata showed decreased susceptibility to fluconazole and itraconazole. Amphotericin B demonstrated excellent antifungal activity against all Candida species. Univariate analyses showed that IC patients with C. albicans had a higher ratio of older age (p = 0.008), solid tumor (p = 0.029), and hypoproteinemia (p = 0.019), whereas those with C. non-albican...Continue Reading

References

Jun 1, 1988·American Journal of Infection Control·J S GarnerJ M Hughes
Jun 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D Abi-SaidS Vartivarian
Aug 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C ViscoliF Meunier
Jun 22, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·H M BlumbergUNKNOWN National Epidemiology of Mycoses Survey(NEMIS) Study Group
Jul 27, 2001·Epidemiology and Infection·T L LamagniE M Johnson
Aug 7, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M M McNeilD W Warnock
Oct 15, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Olafur GudlaugssonDaniel Diekema
Nov 1, 2003·The Lancet Infectious Diseases·Philippe EggimannDidier Pittet
Aug 13, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hilmar WisplinghoffMichael B Edmond
Sep 11, 2004·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Daniel J Diekema, Michael A Pfaller
Apr 9, 2005·BMC Infectious Diseases·Ming-Fang ChengHsiu-Jung Lo
Sep 21, 2006·Infectious Disease Clinics of North America·Peter G Pappas
Jan 16, 2007·Clinical Microbiology Reviews·M A Pfaller, D J Diekema
Dec 3, 2009·JAMA : the Journal of the American Medical Association·Jean-Louis VincentUNKNOWN EPIC II Group of Investigators
Mar 26, 2010·Pharmacotherapy·Heather M ArnoldMarin H Kollef
Aug 28, 2010·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Matthew E FalagasKonstantinos Z Vardakas
Dec 21, 2010·Critical Care Medicine·Daniel H KettUNKNOWN Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators
Jan 10, 2012·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Almudena Moreno Elola-OlasoRoberto Gedaly
Apr 2, 2013·The Journal of Antimicrobial Chemotherapy·Fengmei GuoUNKNOWN China-SCAN Team

❮ Previous
Next ❯

Citations

Jul 22, 2015·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Ming-Chi LiWen-Chien Ko
Dec 3, 2015·International Journal of Antimicrobial Agents·A El ZakhemS S Kanj
Aug 6, 2016·The Journal of Antimicrobial Chemotherapy·B LissH Wisplinghoff
Jan 27, 2018·Journal of Fungi·Małgorzata BondarykZofia Urbańczyk-Lipkowska
Jan 31, 2018·Frontiers of Medicine·Min ChenWanqing Liao
Nov 17, 2020·Frontiers in Cellular and Infection Microbiology·Yaling LiXiuhao Guan
Jul 16, 2019·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Ming-Horng TsaiJang-Jih Lu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.